According to the Zhitong Finance App, Luye Pharmaceutical (02186) announced the results for the year ended December 31, 2023. The group achieved revenue of 6.143 billion yuan (RMB, same below) during the period, an increase of 2.7%; profit attributable to shareholders was 533 million yuan, a decrease of 11.94% year on year; basic profit per share was 14.29 points.

During the reporting period, the sales revenue of the Group's oncology products decreased to RMB 2.122 billion, down about RMB 184 million or 8.0% from the year ended 31 December 2022, mainly due to lack of sales of R&D oncology products during the year; sales revenue of cardiovascular system products increased to 1,687 billion yuan, an increase of about 152 million yuan or 9.9% from RMB 1,536 billion for the year ended 31 December 2022, mainly due to the increase in sales of the Group's various cardiovascular system products; sales revenue of digestive and metabolic products decreased to 4.5 billion yuan 100 million yuan, a decrease of about 182 million yuan or 28.8% from 632 million yuan for the year ended 31 December 2022, mainly due to a decrease in sales of the Group's various other digestive and metabolic products; revenue from central nervous system products increased to 1,695 billion yuan, an increase of about 372 million yuan or 28.1% from 1,323 million yuan for the year ended 31 December 2022.

The Group is laying out a global supply chain, establishing 8 production bases around the world, and establishing a GMP quality management and control system in line with international standards. With more than 30 products covering treatment fields such as central nervous system (central nervous system), oncology, cardiovascular and metabolism, the Group's business reach extends to more than 80 countries and regions around the world, including the largest pharmaceutical markets — China, the United States, Europe and Japan, as well as rapidly developing emerging markets.